Van ECK Associates Corp lessened its position in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 4.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 103,278 shares of the medical research company’s stock after selling 5,136 shares during the period. Van ECK Associates Corp owned about 0.05% of IQVIA worth $23,879,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Empirical Finance LLC lifted its stake in shares of IQVIA by 12.7% in the first quarter. Empirical Finance LLC now owns 3,538 shares of the medical research company’s stock worth $818,000 after buying an additional 398 shares in the last quarter. PFG Private Wealth Management LLC bought a new position in shares of IQVIA in the first quarter worth approximately $271,000. Catalyst Capital Advisors LLC bought a new position in shares of IQVIA in the fourth quarter worth approximately $38,000. Truist Financial Corp lifted its stake in shares of IQVIA by 8.5% in the first quarter. Truist Financial Corp now owns 305,943 shares of the medical research company’s stock worth $70,738,000 after buying an additional 23,863 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. raised its holdings in shares of IQVIA by 14.0% during the first quarter. Whittier Trust Co. of Nevada Inc. now owns 28,657 shares of the medical research company’s stock valued at $6,626,000 after purchasing an additional 3,515 shares during the last quarter. Institutional investors own 87.12% of the company’s stock.
IQVIA Stock Performance
Shares of NYSE IQV opened at $244.71 on Wednesday. The company has a debt-to-equity ratio of 2.36, a current ratio of 0.96 and a quick ratio of 0.96. The firm has a fifty day moving average price of $219.66 and a 200-day moving average price of $223.52. IQVIA Holdings Inc. has a 1 year low of $194.67 and a 1 year high of $285.61. The stock has a market cap of $45.64 billion, a PE ratio of 40.85, a price-to-earnings-growth ratio of 2.27 and a beta of 1.32.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on the stock. Robert W. Baird boosted their price objective on shares of IQVIA from $260.00 to $265.00 in a report on Friday, July 22nd. Barclays decreased their price objective on shares of IQVIA from $240.00 to $236.00 and set an “overweight” rating for the company in a report on Wednesday, July 13th. Guggenheim upped their target price on shares of IQVIA to $246.00 in a report on Friday, July 22nd. Wells Fargo & Company cut shares of IQVIA from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $290.00 to $235.00 in a report on Monday, April 25th. Finally, SVB Leerink assumed coverage on shares of IQVIA in a report on Friday, July 15th. They set an “outperform” rating and a $256.00 target price for the company. Two research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $274.44.
IQVIA Company Profile
IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
- Get a free copy of the StockNews.com research report on IQVIA (IQV)
- Are These 3 Video Game Stocks Now In Play?
- 2 Long-Term EV Plays Trading Under $20
- Exxon, Occidental Petroleum Lead Heavy Month Of Insider Buying
- Why Apple is Primed to Take a Bite Out of Live Sports
- Home Depot Results Point To Sluggish 2nd Half
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.